ACUTE LYMPHOBLASTIC LEUKEMIA

This study reviewed medical records of 37 adults with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) who took asciminib because other treatments stopped working or caused side effects. Researchers wanted to see how many patients achieved complete remission within th…

This study tested a new way to treat blood cancers like leukemia in 16 adults who did not have a standard bone marrow donor. Doctors used a single unit of cord blood that was grown in a lab to increase the number of stem cells before transplant. The goal was to see if this method…

This study tested whether the drug siltuximab can lessen the severity of cytokine release syndrome (CRS) and neurological side effects (ICANS) that often occur after CAR-T cell therapy for blood cancers like lymphoma and leukemia. Twenty-four participants received siltuximab alon…

This phase 2 trial tested a combination of intravenous busulfan, etoposide, and low-dose total-body irradiation before a donor stem cell or bone marrow transplant in 30 patients with advanced leukemia or myelodysplastic syndromes. The goal was to see how well this regimen control…

This large phase 3 trial enrolled over 9,000 children with newly diagnosed standard-risk B-ALL or localized B-LLy. Researchers tested different combinations and doses of chemotherapy drugs to see which worked best with the fewest side effects. The goal was to improve disease-free…

This study tested whether adding the drug tocilizumab to standard care could reduce the risk of graft-versus-host disease (GVHD) after a cord blood transplant in adults with blood cancers. GVHD is a serious complication where donor cells attack the patient's body. Tocilizumab blo…

This study tested different drug combinations to prevent graft-versus-host disease (GVHD) in 174 people with blood cancers receiving stem cells from an unrelated donor. GVHD is a serious side effect where donor cells attack the patient's body. The goal was to find which drug regi…

This study tested a combination of chemotherapy drugs in 318 adolescents and young adults (ages not specified but typically 15-39) with newly diagnosed acute lymphoblastic leukemia (ALL). The goal was to see how well the treatment worked at killing cancer cells and stopping the d…

This phase 1 trial tested a new therapy called CD22-CAR T cells in 134 children and young adults (ages 1-39) with B-cell leukemia or lymphoma that had not been cured by standard treatments. The therapy involves taking a patient's own white blood cells, modifying them in a lab to …

This study tested a program to help children with acute lymphoblastic leukemia (ALL) take their daily chemotherapy medication (mercaptopurine) as prescribed during maintenance therapy. 570 children in remission were randomly assigned to either the intervention program or standard…

This study tested a personalized geriatric optimization plan (GO!) in 30 adults aged 60 and older who were getting a donor stem cell transplant for blood cancers or bone marrow failure. The plan included tailored advice on diet, sleep, activity, and medications to improve physica…

This study tested whether adding pacritinib to standard immune-suppressing drugs (sirolimus and tacrolimus) could prevent graft-versus-host disease (GVHD) in 40 patients receiving stem cell transplants for blood cancers. GVHD occurs when donor immune cells attack the recipient's …

This study tested a new way to prepare patients with relapsed or hard-to-treat acute leukemia for a donor stem cell transplant. It combined a precise form of radiation therapy (IMRT) with two chemotherapy drugs (etoposide and cyclophosphamide) before the transplant. The goal was …

This study tested a new way to give radiation before a stem cell transplant for people aged 16 to 45 with acute lymphoblastic leukemia (ALL). The goal was to see if targeting radiation only to the bone marrow and lymph nodes (called TMLI) is safe and works as well as full-body ra…

This study looked at whether children with cancer and a fever caused by low white blood cells can safely stop antibiotics earlier than usual. 55 children took part, and half stopped antibiotics once their fever was gone for 48 hours, while the other half continued until their whi…

This study looked at 800 children with acute lymphoblastic leukemia to compare two forms of the drug asparaginase: a pegylated version given through a vein and a standard version given as a shot. The goal was to see which caused fewer serious side effects like allergic reactions,…

This early-phase study tested a new treatment called PRGN-3007 UltraCAR-T cells in 3 adults with advanced blood cancers (like leukemia and lymphoma) or triple-negative breast cancer. The goal was to find a safe dose and see if the therapy can shrink tumors. The study is now compl…

This early-stage trial tested the safety and best dose of flotetuzumab, an antibody drug, in 13 patients with advanced blood cancers that had come back or stopped responding to treatment. The drug works by blocking cancer cell growth. The main goal was to see what side effects oc…

This study tested whether a low dose of the drug cyclophosphamide, given after a stem cell transplant, can prevent graft-versus-host disease (GVHD) — a common and serious complication where donor cells attack the patient's body. The trial involved 35 adults with various blood dis…

This study tested whether brushing teeth is safe for patients with prolonged aplasia (low blood cell counts) after intensive chemotherapy. Currently, many hospitals only allow mouthwash to avoid bleeding and infection. The trial compared brushing with an extra-soft toothbrush plu…

This study tested a personalized, intensive treatment plan for adults aged 18-55 with newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma. The approach used strong chemotherapy, targeted drugs like nelarabine for T-cell ALL, and risk-based stem cell trans…

This study tested whether adding the drug abatacept to standard medications (calcineurin inhibitor and methotrexate) could better prevent severe acute graft-versus-host disease (aGVHD) after a stem cell transplant from an unrelated donor. A total of 186 participants aged 6 and ol…

This study tested a stem cell transplant from half-matched (haploidentical) family donors for 34 people with various blood cancers. Patients received a reduced-intensity conditioning regimen of fludarabine, melphalan, and total body irradiation before the transplant. The goal was…

This study tested a drug called inotuzumab ozogamicin in 44 Chinese adults whose acute lymphoblastic leukemia (ALL) had come back or stopped responding to treatment. The drug targets a protein called CD22 on leukemia cells to destroy them. The main goal was to see how many patien…

This study tested adding a drug called thiotepa to the usual chemotherapy given before a donor stem cell transplant for people with leukemia. The goal was to see if this stronger mix could help more patients stay cancer-free one year after the transplant. The study included 40 ad…

This early-phase trial tested a combination of two drugs—veliparib and temozolomide—in 66 adults with relapsed or refractory acute leukemias. Veliparib blocks a DNA repair enzyme, while temozolomide damages cancer cell DNA. The goal was to find the safest dose and check for side …

This early-phase trial tested replacing the standard drug cyclophosphamide with bendamustine after a half-matched bone marrow transplant in 50 patients with various blood cancers. The goal was to see if this change could reduce side effects like graft-versus-host disease while st…

This phase II study tested a personalized dosing approach for the chemotherapy drug L-asparaginase in 100 adults aged 18-50 with newly diagnosed acute lymphoblastic leukemia (ALL). The goal was to see if adjusting doses based on individual drug levels could help more patients com…

This study tested whether a combination of two drugs, cyclophosphamide and abatacept, could lower the risk of chronic graft-versus-host disease (GVHD) after a stem cell transplant in people with high-risk blood cancers. GVHD happens when donor cells attack the patient's body. The…

This study tested whether the drug palifermin could make stem cell transplants safer and reduce chronic graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. Thirty-four adults with blood cancers received palifermin before transplan…

This study looked at 72 children aged 10-18 who finished chemotherapy for acute lymphoblastic leukemia. Researchers compared two types of aerobic exercise—one with a steady intensity and one that gradually increases—to see which better improves heart and lung fitness. All kids ex…

This study tested whether a hybrid (in-person and online) physiotherapy program is feasible for children aged 4-17 with acute lymphoblastic leukemia. Ten children and their parents tried the program, which included tailored exercises and games. The goal was to see if families cou…

This pilot study tested whether PET-CT scans can detect leukemia that has spread outside the bone marrow in patients with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia (ALL). Ten participants received a PET scan before and after CAR T-cell therapy. The goal was to…

This study investigates whether certain genetic differences make children with nephroblastoma (kidney cancer) or acute lymphoblastic leukemia (blood cancer) more likely to develop a serious liver condition called hepatic veno-occlusive disease (VOD) during chemotherapy. Researche…

This study looked back at 621 children in Denmark who had chemotherapy for acute leukemia between 2008 and 2022. The goal was to find out how many got serious mold infections and what factors made it more likely. The results will help doctors better protect children during treatm…

This study looked at whether children and teens who had a stem cell transplant for leukemia could use an iPad-based brain-training program. The main goal was to see if the program was practical and if kids would stick with it. Only 17 participants were enrolled, and the study foc…

This study looked at levels of certain blood clotting proteins (antithrombin III, protein C, protein S, and D-dimer) in 60 people with acute leukemia and compared them to 30 healthy volunteers. The goal was to see if these proteins are different in leukemia patients. No treatment…

This study followed 89 children who finished chemotherapy for acute lymphoblastic leukemia (ALL) to see how their immune systems bounced back. Researchers measured antibody levels for vaccine-preventable diseases and tracked infections during the first year off treatment. The goa…

This completed study looked at 24 children with acute lymphoblastic leukemia to see if tiny cell fragments called microparticles contribute to dangerous blood clots during treatment. Researchers collected blood samples to measure these particles and a clotting protein on their su…

This study looked at 1,753 patients needing a stem cell transplant for blood cancers or other serious blood disorders. Researchers compared two strategies: first searching for a matched unrelated donor, then trying an alternative donor if needed, versus going straight to an alter…

This study looked back at the medical records of 84 people with acute lymphoblastic leukemia (ALL) who received a drug called anti-CD22 outside of clinical trials. The goal was to see how safe and effective the treatment was in everyday hospital use. Researchers collected informa…

This completed study analyzed data from 249 adults with blood cancers like lymphoma and leukemia who received immunotherapy. The goal was to find markers—such as patient history or lab results—that could predict who will respond well and who might have severe side effects. By ide…